Table 1:
Patient Demographics (n = 127)*
| Characteristic | n (%) |
|---|---|
| Age – median (IQR) | 52 (41, 59) |
| Gender | |
| Male | 78 (61) |
| Female | 49 (39) |
| Underlying Disease | |
| Acute leukemia | 60 (47) |
| Lymphoma | 16 (13) |
| Myelodysplastic Syndrome | 14 (11) |
| Chronic leukemia | 12 (9) |
| Myelofibrosis | 8 (6) |
| Multiple myeloma | 8 (6) |
| Myeloproliferative disorder | 3 (2) |
| Aplastic anemia | 3 (2) |
| Other | 3 (2) |
| Donor | |
| Unrelated | 88 (69) |
| Related Sibling | 31 (24) |
| Haploidentical | 8 (6) |
| Graft | |
| PBSC | 110 (87) |
| Cord blood | 9 (7) |
| Bone Marrow | 8 (6) |
| Conditioning | |
| Myeloablative | 79 (62) |
| Non-Myeloablative | 48 (48) |
| CMV Status | |
| Recipient positive | 58 (46) |
| Recipient negative | 69 (54) |
| GVHD prevention | |
| Tacrolimus/MTX | 55 (43) |
| Cyclosporine/MMF | 41 (32) |
| Tacrolimus/MMF | 8 (6) |
| Combination with Rapamycin | 6 (5) |
| Other combination | 17 (13) |
| GVHD grade 2 | 108 (85) |
| grade 3 | 17 (13) |
| grade 4 | 2 (2) |
| GVHD location | |
| Skin and Gut | 68 (54) |
| Gut only | 46 (36) |
| Skin only | 13 (10) |
| Initial Glucocorticoid Dose | |
| 2 mg/kg/day | 26 (21) |
| 1 mg/kg/day | 65 (51) |
| 0.5 mg/kg/day | 36 (28) |
Abbreviations: IQR – interquartile range; GVHD – graft-versus-host disease; MTX – methotrexate; MMF – mycophenolate; CMV – cytomegalovirus
*
percentages may not equal 100% due to rounding